PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Korean Journal of Pediatrics10.3345/kjp.2019.0011520196210400-404Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patientsSu Yeong Kim, Na Mi Lee, Sin Weon Yun, Soo Ahn Chae, In Seok Lim, Eung Sang Choi, Dae Yong Yihttp://kjp.or.kr/upload/pdf/kjp-2019-00115.pdf, http://kjp.or.kr/journal/view.php?doi=10.3345/kjp.2019.00115, http://kjp.or.kr/upload/pdf/kjp-2019-00115.pdf
Journal of Clinical Medicine10.3390/jcm10173905202110173905Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal CalprotectinEdyta Szymanska, Aldona Wierzbicka, Maciej Dadalski, Jaroslaw Kierkushttps://www.mdpi.com/2077-0383/10/17/3905/pdf
Alimentary Pharmacology & Therapeutics10.1111/j.1365-2036.2011.04707.x2011342243-251Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary preventionS. D. Saini, A. M. Fendrick, J. M. Scheimanhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2011.04707.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2011.04707.x/fullpdf
Alimentary Pharmacology & Therapeutics10.1046/j.1365-2036.17.s1.1.x2003171-4Review article: esomeprazole − the first proton pump inhibitor to be developed as an isomerM. J. Kendallhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.17.s1.1.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.17.s1.1.x/fullpdf
Gastroenterology10.1016/s0016-5085(08)61879-x20081344A-402M1709 Proton Pump Inhibitor Based Triple Therapy Combined with Bismuth Is Superior to Proton Pump Inhibitor Based Triple Therapy Only for Helicobacter pylori Eradication. (Preliminary Data)HyunJin Jo, Dong Ho Leehttps://api.elsevier.com/content/article/PII:S001650850861879X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S001650850861879X?httpAccept=text/plain
Inflammatory Bowel Diseases10.1093/ibd/izaa347.014202127Supplement_1S6-S6EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITISWilliam Sandborn, Brian Feagan, Douglas Wolf, Geert D’Haens, Séverine Vermeire, Stephen Hanauer, Subrata Ghosh, Harry Southworth, Sarah Harrishttp://academic.oup.com/ibdjournal/article-pdf/27/Supplement_1/S6/35931478/izaa347.014.pdf, http://academic.oup.com/ibdjournal/article-pdf/27/Supplement_1/S6/35931478/izaa347.014.pdf
Gastroenterology10.1053/j.gastro.2021.01.05120211603S8-S9EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITISWilliam Sandborn, Brian Feagan, Douglas Wolf, Geert D’Haens, Séverine Vermeire, Stephen Hanauer, Subrata Ghosh, Harry Southworth, Sarah Harrishttps://api.elsevier.com/content/article/PII:S0016508521001189?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508521001189?httpAccept=text/plain
Journal of Crohn's and Colitis10.1093/ecco-jcc/jjab232.402202216Supplement_1i311-i312P275 New non-invasive biomarkers of intestinal inflammation in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin – pilot studyE Szymanska, J Bierla, A Wierzbicka, M Dadalski, E Konopka, B Cukrowska, J Kierkushttps://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i311/42251460/jjab232.402.pdf, https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i311/42251460/jjab232.402.pdf
Clinica Chimica Acta10.1016/j.cca.2012.11.008201341641-47Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfortEmanuel Burri, Michael Manz, Claude Rothen, Livio Rossi, Christoph Beglinger, Frank Serge Lehmannhttps://api.elsevier.com/content/article/PII:S0009898112005487?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0009898112005487?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(17)32958-x20171525S860Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal EosinophiliaMarco Della Coletta, Nicola de Bortoli, Ottavia Bartolo, Salvatore Tolone, Giorgia Bodini, Elisa Marabotto, Patrizia Zentilin, Vincenzo Savarino, Edoardo V. Savarinohttps://api.elsevier.com/content/article/PII:S001650851732958X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S001650851732958X?httpAccept=text/plain